This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Efficacy and Safety of Oral Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) in Patients With Mild to Moderately Active Ulcerative Colitis | MicrobiomeTrials
← Back to trials NCT06488625
Efficacy and Safety of Oral Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) in Patients With Mild to Moderately Active Ulcerative Colitis Recruiting PHASE2, PHASE3 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2024-09-12Est. Completion: 2027-10
Enrollment target: 459 participantsLocations Gastroenterologische Schwerpunktpraxis Prof. Dr. Ludwig & Dr. med. Güthle, Dornstadt, Baden-Wurttemberg, Germany Private Practice for Gastroenterology, Heidelberg, Baden-Wurttemberg, Germany Universitat Heidelberg, Mannheim, Baden-Wurttemberg, Germany Universitaetsklinikum Ulm AöR, Ulm, Baden-Wurttemberg, Germany Universitaetsklinikum Augsburg, Augsburg, Bavaria, Germany Sozialstiftung Bamberg, Bamberg, Bavaria, Germany Medical Care Unit Dachau, Dachau, Bavaria, Germany University Medical Center Hamburg-Eppendorf, Hamburg, Free and Hanseatic City of Hamburg, Germany Gesundheit Nord gGmbH Klinikverbund Bremen, Bremen, Free Hanseatic City of Bremen, Germany Gastroenterologie am Herrengarten, Darmstadt, Hesse, Germany Agaplesion Frankfurter Diakonie Kliniken gGmbH, Frankfurt am Main, Hesse, Germany Goethe University Frankfurt, Frankfurt am Main, Hesse, Germany Practice for Gastroenterology, Hanover, Lower Saxony, Germany Universitaetsklinikum Aachen AöR, Aachen, North Rhine-Westphalia, Germany Evangelisches Krankenhaus Kalk gGmbH, Cologne, North Rhine-Westphalia, Germany Other microbiome trials you might be interested in Inflammatory Bowel Diseases (IBD) Crohn Disease Colitis, Ulcerative
Difficult-to-treat inflammatory bowel disease (DTT-IBD) represents a heterogeneous group of patients with treatment-refr…
Multiple Locations Est. completion Oct 31, 2032
Inflammatory Bowel Disease
This study evaluates oral Lactobacillus reuteri as an adjunct therapy for 2 months. Endoscopic assessments will be perfo…
Suqian, China Completed Mar 30, 2026
Gastropraxis an der St. Barbara-Klinik, Hamm, North Rhine-Westphalia, Germany
Universitaet Muenster, Münster, North Rhine-Westphalia, Germany
St. Marien Und St. Annastiftskrankenhaus, Ludwigshafen am Rhein, Rhineland-Palatinate, Germany
Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöR, Dresden, Saxony, Germany
Martin-Luther-Universitaet Halle-Wittenberg, Halle, Saxony-Anhalt, Germany
Gastropraxis Magdeburg, Magdeburg, Saxony-Anhalt, Germany
Universitaetsklinikum Schleswig-Holstein AöR, Kiel, Schleswig-Holstein, Germany
Universitaetsklinikum Schleswig-Holstein AöR, Lübeck, Schleswig-Holstein, Germany
Charite Universitaetsmedizin Berlin KöR, Berlin, State of Berlin, Germany
Charite Universitaetsmedizin Berlin KöR, Berlin, State of Berlin, Germany Recruiting
Recurrent C. Difficile (rCDI) Ulcerative Colitis (UC) Metabolic Syndrome (MetS)
The gut microbiota plays a key role in immunity and metabolism and contributes to diseases such as recurrent C. difficil…
Rome, Italy Est. completion Jan 19, 2029